Suven Life Sciences, a biopharmaceutical company, witnessed a rise in share price after the company announced, it has secured patents in Australia, China, Europe, South Korea and United States of America. The secured patents are for CNS therapy through mechanism of action - H3 Inverse agonist.

The granted claims of the patent include the class of selective H3 ligands discovered by the company and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders.

Venkat Jasti, CEO of Suven said, "We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally."

With these new patents, Suven has a total of twenty two granted product patents in Australia, nineteen granted patents from China, seventeen granted patents from Europe, seventeen granted patents from South Korea and twenty three granted patents from USA.

Shares of Suven Life Sciences are trading at Rs 290.30, up Rs 11.4, or 4.09% at the Bombay Stock Exchange (BSE) on Tuesday at 12:20 p.m.

The scrip has touched an intra-day high of Rs 295.90 and low of Rs 278.90. The total volume of shares traded at the BSE is 363,083.